Core Thesis - Achieve Life Sciences, Inc. (ACHV) is positioned for significant growth as it awaits FDA approval for cytisinicline, a non-nicotine therapy for smoking addiction, with a decision expected by June 20, 2026 [3] Company Overview - ACHV is a late-stage pharmaceutical company focused on developing and commercializing cytisinicline for nicotine independence in Canada, the U.S., and the U.K. [3] - The company has a market capitalization of approximately $250 million and aims to position cytisinicline as a best-in-class alternative to existing smoking cessation drugs [3] Product Efficacy and Safety - Cytisinicline has a long history of safe use in Europe and has shown strong efficacy and tolerability in the U.S., supported by two successful Phase 3 trials and a long-term safety study [4] - The treatment has not been associated with serious adverse events, enhancing its profile as a potential FDA-approved therapy [4] Market Opportunity - There are about 29 million smokers in the U.S., with over half attempting to quit each year, but fewer than 10% succeed, highlighting a significant unmet medical need for effective smoking cessation therapies [4] - ACHV is also pursuing approval for vaping cessation, where no FDA-approved therapies currently exist, and cytisinicline has received Breakthrough Therapy designation [5] Financial Position - As of Q3 2025, ACHV had $48 million in cash, providing sufficient runway through the FDA decision, although additional capital will likely be needed for commercialization [5] - If approved, cytisinicline could access a large, reimbursed market with limited competition, potentially leading to a significant re-rating of ACHV as it transitions to a commercial-stage company [5] Stock Performance - ACHV's stock price has appreciated approximately 56.55% since March 2025, driven by advancing FDA milestones and improving approval visibility [6]

Core Insights - Achieve Life Sciences Inc. (NASDAQ:ACHV) is currently viewed as a promising investment opportunity, particularly among Canadian penny stocks, with a Buy rating maintained at a price target of $11.00 [1] - The FDA has accepted Achieve Life Sciences' New Drug Application (NDA) for cytisinicline, aimed at smoking cessation, with a targeted action date set for June 20, 2026 [2] - The acceptance of the NDA highlights the company's commitment to addressing nicotine dependence, a condition that has not seen new therapies in nearly two decades [3] Financial Overview - As of the end of the third quarter, Achieve Life Sciences reported cash and cash equivalents of $48.1 million, with total operating expenses for the quarter amounting to $14.7 million [4] - The company experienced a net loss of $14.4 million for the third quarter and a total net loss of $40 million for the first nine months of the year [4] Company Focus - Achieve Life Sciences is a specialty pharmaceutical company dedicated to developing and commercializing cytisinicline to combat nicotine dependence and the broader smoking and vaping epidemic [5] - The company has successfully completed Phase 3 studies for smoking cessation and has submitted the NDA to the FDA for this indication [5]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Artiva Biotherapeutics, Inc. (ARTV) has increased by 124% to $6.22 [3] - Akanda Corp. (AKAN) is up 39% at $3.10 [3] - Kezar Life Sciences, Inc. (KZR) has risen 38% to $5.80 [3] - Carbon Revolution Public Limited Company (CREV) is also up 38% at $5.15 [3] - Safe & Green Holdings Corp. (SGBX) has increased by 28% to $3.96 [3] - Achieve Life Sciences, Inc. (ACHV) is up 23% at $3.80 [3] - Revolution Medicines, Inc. (RVMD) has risen 8% to $53.90 [3] - Erayak Power Solution Group Inc. (RAYA) is up 8% at $5.76 [3] - ProQR Therapeutics N.V. (PRQR) has increased by 7% to $3.00 [3] - Bio Green Med Solution, Inc. (BGMS) is up 6% at $4.04 [3] Premarket Losers - American Rebel Holdings, Inc. (AREB) has decreased by 41% to $2.09 [4] - Sadot Group Inc. (SDOT) is down 25% at $5.35 [4] - AVITA Medical, Inc. (RCEL) has fallen 24% to $4.04 [4] - Soluna Holdings, Inc. (SLNH) is down 23% at $3.22 [4] - American Battery Technology Company (ABAT) has decreased by 17% to $4.70 [4] - CID HoldCo, Inc. (DAIC) is down 17% at $2.16 [4] - Pinnacle Food Group Limited (PFAI) has fallen 12% to $3.12 [4] - OnKure Therapeutics, Inc. (OKUR) is down 12% at $2.52 [4] - Whitehawk Therapeutics, Inc. (WHWK) has decreased by 12% to $2.29 [4] - Aqua Metals, Inc. (AQMS) is down 7% at $14.50 [4]

Group 1: CSX Corp Performance - CSX Corp reported third-quarter revenue of $3.59 billion, exceeding analyst estimates of $3.58 billion [1] - The company achieved adjusted earnings of 44 cents per share, surpassing analyst expectations of 43 cents per share [1] - Following the earnings report, CSX shares increased by 4.2% to $37.51 in pre-market trading [1] Group 2: Other Stocks in Pre-Market Trading - Artiva Biotherapeutics Inc gained 98.6% to $5.50 after receiving FDA Fast Track Designation for AlloNK [4] - Safe & Green Holdings Corp surged 38.8% to $4.27 after completing Phase 1 of its intelligent wellsite monitoring system [4] - Kezar Life Sciences Inc rose 36% to $5.67 following a regulatory update on its Zetomipzomib program [4] - INVO Fertility Inc tumbled 34.6% to $0.92 after a significant rise of over 85% the previous day [4] - American Battery Technology Co shares dipped 19.8% to $4.55 after a 37% decline on Thursday due to the termination of a grant by the Department of Energy [4]

Appointments - Joao Laranjo was appointed as the chief financial officer of Stellantis, retaining his role as CFO of Stellantis North America, a position he has held since February 2025 [2] - Bryan Castellani joined Genius Sports as CFO, previously serving as CFO of Warner Music Group and holding executive roles at ESPN and Disney [3] - Dan Feeley was named finance chief and treasurer of The Metropolitan Museum of Art, having previously served as chief budget and planning officer since 2021 [4] - Steve Rai was hired as CFO of OpenText, previously serving as CFO of BlackBerry Limited and holding senior finance positions at PMC-Sierra and PricewaterhouseCoopers [5] - Jason Yee was promoted to chief financial officer at Achieve, having served as executive vice president of corporate development and strategy for nine years [6]

Core Insights - Achieve Life Sciences has partnered with Omnicom as its strategic innovation partner to support the U.S. commercial launch of cytisinicline, a treatment for nicotine dependence [1][2][3] - The collaboration aims to leverage advanced technologies and a comprehensive marketing strategy to address a significant public health issue related to smoking cessation [4][5] Company Overview - Achieve Life Sciences is a late-stage specialty pharmaceutical company focused on developing and commercializing cytisinicline for smoking cessation, having submitted its New Drug Application (NDA) to the FDA on June 25, 2025 [7] - The company has completed two Phase 3 studies and is currently conducting an open-label safety study for cytisinicline [4][7] Industry Context - Smoking is the leading cause of preventable death in the U.S., with over 29 million adults still smoking [4][8] - Cytisinicline is positioned as a potential breakthrough treatment for nicotine dependence, with the FDA granting it Breakthrough Therapy designation [8][9] Marketing Strategy - Omnicom's approach includes utilizing AI-enabled marketing technology to enhance targeting and engagement with healthcare professionals and patients [2][5] - The integrated team from Omnicom will provide expertise in consumer brand development, medical education, and strategic public relations to support the launch [3][4] Technological Integration - The collaboration will incorporate innovative technologies such as generative AI, predictive analytics, and social listening to improve targeting and personalization [5][6] - Partnerships with healthcare apps, pharmacies, and data providers will further expand the reach and insights of Achieve's marketing strategy [5]

Core Insights - Achieve Life Sciences announced significant results from the ORCA-3 trial, demonstrating that cytisinicline effectively aids in smoking cessation by increasing quitting rates and reducing nicotine cravings compared to placebo [1][2][4] Company Overview - Achieve Life Sciences is a late-stage specialty pharmaceutical company focused on developing cytisinicline for nicotine dependence and smoking cessation [7][8] - The company plans to submit a New Drug Application (NDA) for cytisinicline to the FDA in June 2025 [1][5] Clinical Trial Details - The ORCA-3 trial involved 792 U.S. adults, assessing the efficacy of cytisinicline over 6 and 12 weeks, with results published in JAMA Internal Medicine [1][6] - Participants had an average age of 53 years, smoked a median of 20 cigarettes per day, and had a median smoking history of 36 years [3][6] - Cytisinicline was administered at a dosage of 3mg three times daily, with behavioral support provided throughout the trial [6] Efficacy and Tolerability - Cytisinicline showed a significant increase in the odds of smoking cessation and a reduction in nicotine cravings, leading to decreased nicotine intake among participants [4][5] - The drug was well tolerated, attributed to its selective binding to nicotine receptors with limited off-target effects [2][4] Market Context - Tobacco use is the leading cause of preventable death, with over 8 million deaths globally and nearly half a million in the U.S. annually [9] - There is a critical need for effective smoking cessation treatments, as current options are limited [5][9]

Financial Data and Key Metrics Changes - As of December 31, 2024, the company's cash, cash equivalents, and marketable securities were $34.4 million, up from $15.6 million on December 31, 2023, indicating a significant increase in liquidity [34] - Total operating expenses for Q4 2024 were $12.2 million, and for the year ended December 31, 2024, they were $39.1 million, reflecting the company's ongoing investment in its strategic initiatives [35] - The net loss for Q4 2024 was $12.4 million, and for the year, it was $39.8 million, showing a consistent financial performance as the company transitions towards commercialization [35] Business Line Data and Key Metrics Changes - The company is focused on the NDA submission for cytisinicline, a treatment for nicotine dependence, with a planned submission by the end of Q2 2025 [7][43] - The ORCA Open Label Long-Term Safety Exposure clinical trial has completed enrollment with 479 participants, meeting FDA requirements for the NDA submission [11][18] Market Data and Key Metrics Changes - The company aims to address the nicotine dependence crisis, which affects approximately 29 million Americans, with 15 million attempting to quit each year [14] - The health risks associated with smoking and vaping are becoming increasingly recognized, emphasizing the need for effective treatment options like cytisinicline [9] Company Strategy and Development Direction - Achieve Life Sciences is transitioning from a clinical to a commercial company, with a focus on launching cytisinicline as a first-in-class treatment for nicotine dependence [12][23] - The company is also preparing for a Phase 3 trial for vaping cessation, with plans to initiate it in the first half of 2026, depending on financing [21][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the NDA submission process and the potential of cytisinicline to become a best-in-class treatment for nicotine dependence [23][43] - The company is committed to effective cash management to support its strategic goals and maximize shareholder value [36][44] Other Important Information - The company received Breakthrough Therapy designation for cytisinicline as a treatment for vaping cessation, highlighting its potential impact in the market [11][22] - The management team has been strengthened with new appointments, including a CFO to oversee financial strategy [12] Q&A Session Summary Question: Clarification on NDA submission requirements - Management confirmed that the NDA submission is on track, with all necessary documents being finalized and external consultants assisting in the process [48][50] Question: Commercial access and distribution strategy - The company is considering a specialty pharmacy model to track prescriptions and mitigate access barriers, while also preparing for payer discussions [54][56] Question: Potential partnerships for comorbid indications - Management indicated that while there is interest in partnerships, the primary focus remains on the NDA submission and the U.S. market opportunity [62][90] Question: Future DSMC reviews and CMC readiness - Management confirmed that additional DSMC reviews are expected, and external consultants are being utilized to ensure the NDA's quality [70][72] Question: Sales ramp and market segmentation - The company anticipates a slow sales ramp post-launch, focusing on high-volume prescribers and motivated patients for cytisinicline [80][84] Question: Patient satisfaction with current treatments - Research indicates low satisfaction rates with existing treatments like varenicline, suggesting a strong opportunity for cytisinicline [113][115] Question: Vaping study expectations - The company is preparing for higher placebo rates in future studies and has designed the Phase 3 trial accordingly [144]

Core Viewpoint - Achieve Life Sciences is on track to submit its new drug application (NDA) for cytisinicline, a treatment for nicotine dependence, by the end of Q2 2025, following significant progress in clinical trials and corporate governance [1][3][4]. Company Developments - The company has completed enrollment in the ORCA-OL clinical trial with 479 participants across 29 U.S. sites, focusing on the long-term safety of a 3 mg cytisinicline regimen for smoking and vaping cessation [4]. - Achieve received two positive reviews from the Data Safety Monitoring Committee (DSMC) for the ORCA-OL trial, confirming no unexpected treatment-related adverse events and excellent participant adherence [5]. - The company appointed Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors, enhancing its expertise in corporate strategy and commercialization [6]. - Mark Oki was appointed as Chief Financial Officer in December 2024, bringing over 25 years of experience in financial leadership within the biotechnology and pharmaceutical sectors [7]. Clinical Trial Progress - The ORCA-OL trial met the requirement of at least 300 participants completing six months of treatment, which is essential for the NDA submission [4][8]. - An End-of-Phase 2 meeting with the FDA confirmed that one well-controlled Phase 3 trial (ORCA-V2) would be sufficient for a vaping cessation indication, with plans to initiate this trial in the first half of 2026, depending on funding availability [9]. Financial Overview - As of December 31, 2024, Achieve reported cash, cash equivalents, and marketable securities totaling $34.4 million, with total operating expenses of $39.1 million for the year [10][20]. - The net loss for the fourth quarter and the year ended December 31, 2024, was $12.4 million and $39.8 million, respectively, with a basic and diluted net loss per share of $0.36 and $1.24 [10][20]. Market Context - There are approximately 29 million adults who smoke combustible cigarettes in the U.S., with tobacco use being the leading cause of preventable death [13]. - Over 11 million adults in the U.S. use e-cigarettes, highlighting a significant market opportunity for cytisinicline, which has received Breakthrough Therapy designation from the FDA for vaping cessation [14][15].

Company Overview - Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence and smoking cessation [3] - The company has successfully completed two Phase 3 studies for smoking cessation and one Phase 2 study for vaping cessation, with plans to submit a new drug application in Q2 2025 [3][6] Product Information - Cytisinicline is a plant-based alkaloid that interacts with nicotinic acetylcholine receptors in the brain, aimed at reducing nicotine cravings and the satisfaction associated with nicotine products [6] - Approximately 29 million adults smoke combustible cigarettes in the U.S., with tobacco use being the leading cause of preventable death, responsible for over 8 million deaths globally and nearly half a million in the U.S. annually [4] - There are over 11 million adults in the U.S. who use e-cigarettes, with no FDA-approved treatments specifically for nicotine e-cigarette cessation, highlighting a critical need that cytisinicline aims to address [5] Upcoming Events - Achieve Life Sciences will present at the Barclays 27th Annual Global Healthcare Conference from March 11-13, 2025, with CEO Rick Stewart scheduled to present on March 12, 2025 [1][2]